Loading...
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...
Na minha lista:
| Udgivet i: | Pharmacoecon Open |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6861391/ https://ncbi.nlm.nih.gov/pubmed/31240690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-0138-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|